Navigation Links
New White Paper from Tuberous Sclerosis Alliance Assesses Visual Field Risks of Vigabatrin

SILVER SPRING, Md., Dec. 6, 2013 /PRNewswire-USNewswire/ -- A new white paper from the Tuberous Sclerosis Alliance (TS Alliance), entitled "Vigabatrin-Associated Visual Field Loss (VAVFL): What You Need to Know," was released today at the American Epilepsy Society annual meeting in Washington, DC.  The white paper was written by Darcy A. Krueger, MD, PhD, Associate Professor, Clinical Pediatrics and Neurology, Tuberous Sclerosis Clinic, Cincinnati Children's Hospital. Vigabatrin is approved in the United States by the Food and Drug Administration to treat infantile spasms and medically refractory complex partial seizures that are common in tuberous sclerosis complex (TSC).


"Infantile spasms occur in approximately one-third of children with TSC," says TS Alliance President and CEO Kari Luther Rosbeck. "Because vigabatrin is the first-line medication recommended in the recently released TSC Clinical Consensus Guidelines to treat these types of seizures, it was important to address the medication's side effects, which Dr. Krueger has done in this new white paper." 

"The purpose of this white paper is to provide an authoritative report about vigabatrin-associated visual field loss (VAVFL) based on published clinical reports and studies," Dr. Krueger explains. "This report was written for patients and their families and will help in making an informed decision about the use of vigabatrin to treat infantile spasms and/or complex partial epilepsy." The white paper summarizes and critically evaluates what is known about the prevalence of VAVFL following vigabatrin exposure and possible ways to manage any potential retinal toxicity as reported in published, peer-reviewed publications.  

TSC is a multi-system genetic disorder that causes tumors to form in vital organs, primarily the brain, heart, eyes, kidneys, lungs and skin. It's also the leading genetic cause of both autism and epilepsy.  Approximately 50,000 people in the United States suffer from the disease, and it has an estimated incidence of 1 in 6,000 live births.  More than 1 million people worldwide have TSC.

Formed in 1974, the TS Alliance is the only U.S.-based non-profit organization dedicated to finding a cure for TSC while improving the lives of those affected.  For more information, visit or call 800-225-6872.  The white paper, supported by an unrestricted educational grant from Lundbeck, is available for download at  The new Clinical Consensus Guidelines are available at

For more information contact:
Jaye D. Isham, Vice President, Communications Strategy
(301) 562-9890,

SOURCE Tuberous Sclerosis Alliance
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Improving Outcomes in the Treatment and Management of Metastatic Colorectal Cancer - International White Paper Launched at European Cancer Congress 2013
2. Automation is Revolutionizing White Cell Differential Analysis; New Whitepaper Details How
3. RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care
4. New White Paper Details What Compounding Pharmacies Must Know to Prepare for FDA Inspections
5. Scott & White Hospital - Round Rock first in Central Texas, one of few nationally to perform breakthrough procedure for acid reflux
6. Disinfectant Qualification Questions are Answered for Sterile Drug Manufacturers in New White Paper
7. TeamHealth White Paper Examines Telemedicine Risks, Risk Management Strategies
8. Scott & White to Open Emergency Hospital in Cedar Park
9. Heraeus Expands Its Venus White Line of Whitening Maintenance and Oral Care Products
10. MEI Pharma Announces Retirement Of Chairman Bryan Williams From Board Of Directors And Appointment Of Christine White As Lead Director
11. White Paper Details Five Things to Consider Before Buying Spiral Bevel Gear Drives
Post Your Comments:
(Date:11/26/2015)... UTRECHT , Nederland, November 26, 2015 ... --> Een nieuwe aanpak combineert ... van gevorderde kanker. ... -->      (Photo: ... van het Leids Universitair Medisch Centrum (LUMC) ...
(Date:11/26/2015)... , November 26, 2015 3D bioprinting ... 2022, according to a new report by Grand View Research ... Disease (CKD) which demands kidney transplantation is expected to boost ... effective substitute for organ transplantation. --> 3D bioprinting ... 2022, according to a new report by Grand View Research ...
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Surface Testing Market: Supplier Shares, Competitive ... offering.  --> ) ... "2016 Future Horizons and Growth Strategies ...
Breaking Medicine Technology:
(Date:11/26/2015)... ... November 26, 2015 , ... ... retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes ... titles work with any font, giving users limitless opportunities to stylize and create ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... more aggressive than those found on mammography, according to a study published online ... additional cancers not seen on mammography may necessitate a change in treatment. , ...
(Date:11/25/2015)... MN (PRWEB) , ... November 25, 2015 , ... Finnleo, ... through Christmas Eve on several models of traditional and far-infrared saunas. , ... Nordic Spruce is the most traditional Finnish sauna wood, and Finnleo uses only European ...
(Date:11/25/2015)... ... , ... Dr. John Pierce, Medical Director at the Ageless Forever clinic in ... Capillus272™ Pro laser therapy cap. FDA cleared for safety and efficacy, the Capillus272 offers ... for surgery, prescription pills, or topical foams. , “Capillus272™ Pro is a home-use ...
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert is ... One Beat ” campaign. The partnership between the two groups began in 2014 with ... International’s cause. , MAP International was founded in 1954 and is an international Christian-based ...
Breaking Medicine News(10 mins):